Recent investigations have converged on the intersection of GLP-1|GIP|GCGR activator therapies and dopamine communication. While GIP activators are commonly employed for addressing type 2 diabetes, their unexpected effects on reward circuits, specifically governed by dopamine pathways, are gaining substantial focus. This article provides a concise